Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Arctic Bioscience AS's Other Operating Expense for the
six
months ended in Dec. 2025 was kr22.56 Mil.
Its Other Operating Expense for the trailing twelve months (TTM) ended in Dec. 2025 was kr44.49 Mil.
Arctic Bioscience AS's quarterly Other Operating Expense
declined
from Dec. 2024 (kr30.36 Mil) to Jun. 2025 (kr21.93 Mil) but then
increased
from Jun. 2025 (kr21.93 Mil) to Dec. 2025 (kr22.56 Mil).
Arctic Bioscience AS's annual Other Operating Expense
increased
from Dec. 2023 (kr58.36 Mil) to Dec. 2024 (kr59.68 Mil) but then
declined
from Dec. 2024 (kr59.68 Mil) to Dec. 2025 (kr44.49 Mil).
Arctic Bioscience AS Other Operating Expense Related Terms
Arctic Bioscience AS Other Operating Expense Historical Data
* Premium members only.
The historical data trend for Arctic Bioscience AS's Other Operating Expense can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Arctic Bioscience AS Other Operating Expense Chart
Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)
Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.
Other Operating Expense for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was kr44.49 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Other Operating Expense of kr44.49 Mil mean?
Arctic Bioscience AS (OSL:ABS) has a Other Operating Expense of kr44.49 Mil as of Dec. 2025. Other operating expenses that a company records on its income statement. View historical data on Arctic Bioscience AS and its competitors.
Is Arctic Bioscience AS's Other Operating Expense too high?
Arctic Bioscience AS's current Other Operating Expense is kr44.49 Mil. Overall, Arctic Bioscience AS has a GF Score™ of 58/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Arctic Bioscience AS's Other Operating Expense compare to VRTX and REGN?
Arctic Bioscience AS's Other Operating Expense of kr44.49 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Operating Expense for a Biotechnology company?
A good Other Operating Expense depends on the Biotechnology industry context. However, Other Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Operating Expense mean?
A high Other Operating Expense can signal that a stock is expensive relative to its fundamentals. Other operating expenses that a company records on its income statement. View historical data on Arctic Bioscience AS and its competitors. Arctic Bioscience AS's current Other Operating Expense is kr44.49 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arctic Bioscience AS stock overvalued right now?
Based on GuruFocus' analysis, Arctic Bioscience AS (OSL:ABS) is currently considered Possible Value Trap. The stock's GF Value™ is kr8.77, compared to a current price of kr3.06 — trading 65.1% below its estimated fair value. The current Other Operating Expense is kr44.49 Mil. Arctic Bioscience AS's overall GF Score™ is 58/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Operating Expense calculated?
Other Operating Expense is calculated from a company's financial statements. For Arctic Bioscience AS (OSL:ABS), the current Other Operating Expense is kr44.49 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Arctic Bioscience AS (OSL:ABS) Overvalued in 2026?
Based on GuruFocus' analysis, Arctic Bioscience AS stock appears to be undervalued.
The current stock price of kr3.06 is trading 65.1% below its estimated GF Value™ of kr8.77.
GuruFocus considers Arctic Bioscience AS to be Possible Value Trap.
Key valuation signals for OSL:ABS:
Other Operating Expense: kr44.49 Mil
GF Value™: kr8.77 vs. price of kr3.06 (65.1% below fair value)
No single metric tells the full story. See the OSL:ABS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Arctic Bioscience AS is a clinical-stage biotechnology company working to develop drug candidates within the areas of autoimmune and inflammatory diseases. It is developing pharmaceutical and commercializing nutraceutical products based on bioactive marine compounds, including lipids essential to maintaining cell membranes. The company's proprietary extraction technology is used to extract membrane fats from marine raw materials, such as herring roe and algae. Geographically, the company operates in Norway, the Americas, Europe, and APAC, with the majority of the revenue derived from the Americas.
58GF Score
Get the complete analysis for OSL:ABS
Other Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSL:ABS has been successfully added to your 
